Veracyte Inc (VCYT)

NASD · Healthcare · Diagnostics & Research · USA

Veracyte Inc is a small cap company (market value between $300 million and $2 billion) in the Diagnostics & Research industry.

Veracyte is a global diagnostics company offering molecular tests to help clinicians make cancer diagnosis and treatment decisions. In the United States, it provides laboratory-developed tests through CLIA-certified labs for prostate, thyroid, breast, and bladder cancers. Outside the United States, it distributes in vitro diagnostic tests to hospitals and laboratories.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Veracyte Inc stock.

Our verdict on VCYT

Undervalued: intrinsic value $30.97 per share, market price $24.23, margin of safety 21.8% (as of 2026-11-17).

Discounting its cash flows at 13.6% (average of 3 methods) values the shares at $30.97; the price of $24.23 is 22% below that value, and 64% of that value comes from beyond year five.

ETFs with the most weight in VCYT

17 more funds hold it; the full list is part of the paid plan.

More on VCYT

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Cheaper than VCYT in Diagnostics & Research

Is VCYT undervalued or overvalued?

VCYT is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 13.6% (average of 3 methods) values the shares at $30.97; the price of $24.23 is 22% below that value, and 64% of that value comes from beyond year five.

What is the intrinsic value of VCYT?

$30.97 per share (as of the 2026-11-17 close), against a market price of $24.23. That is a margin of safety of 21.8%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.